Customer Center
Login | Register

Investor Relations

Investor Relations

Upcoming Event
More events are coming soon.

Stock Information

More >>

Recent News

More >>
Date Title  
Toggle Summary Luminex Receives BARDA Contract to Support Development of Second, Rapid SARS-CoV-2 Test
- Follows BARDA Contract and EUA for NxTAG® CoV Extended Panel last week - ARIES® SARS-CoV-2 Assay will be submitted for EUA later this week AUSTIN, Texas , March 31, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received $642,450 in funding from the Biomedical
Toggle Summary Luminex Receives FDA Emergency Use Authorization for NxTAG® CoV Extended Panel to Detect the SARS-CoV-2 Virus that Causes COVID-19 Disease
BARDA award for $642K helped Luminex accelerate development and validation AUSTIN, Texas , March 27, 2020 /PRNewswire/ --  Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its NxTAG ®  CoV Extended